Last updated on June 2020

A Study of BDTX-189 an Orally Available Allosteric ErbB Inhibitor in Patients With Advanced Solid Tumors.


Brief description of study

This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to:

  • Find the recommended dose of BDTX-189 that can be given safely to participants
  • Learn more about the side effects of BDTX-189
  • Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK)
  • Determine the antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations

Detailed Study Description

BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found in 1 - 2 % of most solid tumors and enriched in some cancers with a prevalence of about 2 - 7% such as in non-small cell lung cancer, breast cancer, colorectal cancer, bladder cancer, and endometrial cancer. Currently approved HER2 and EGFR directed therapies are not active against the spectrum of allosteric mutations at relevant and tolerated exposure levels.

This Phase 1/2 multi-center, open-label trial is a first-in-human study that will evaluate BDTX-189 orally administered daily as a single agent in patients with solid tumors harboring select mutations or alterations. The Phase 1 portion is a dose escalation primarily designed to assess the safety and tolerability of BDTX-189 and to determine a recommended Phase 2 dose (RP2D). Phase 1 will focus on patients with a solid tumor with alterations such as:

  • Allosteric HER2 or HER3 mutation(s)
  • EGFR or HER2 exon 20 insertion mutation(s)
  • HER2 amplified or overexpressing tumors
  • EGFR exon 19 deletion or L858R mutation

Following selection of the RP2D, a Phase 2 portion will be initiated to further evaluate the clinical activity of BDTX-189. Phase 2 will focus on patients with a solid tumor harboring

an
  • Allosteric HER2 mutation (including but not limited to S310F/Y, R678Q, L755S/P, V777L, V842I)
  • EGFR or HER2 exon 20 insertion mutation

Eligible mutations must be determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.

Clinical Study Identifier: NCT04209465

Find a site near you

Start Over

Florida Cancer Specialists

Sarasota, FL United States
  Connect »

Tennessee Oncology

Nashville, TN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Florida Cancer Specialists

Lake Mary, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.